Membranous nephropathy: When and how to treat

Slides:



Advertisements
Similar presentations
Management of IgA nephropathy: Evidence-based recommendations
Advertisements

V.M. Campese, N. Mitra, D. Sandee  Kidney International 
Isolated Systolic Hypertension: An Update After SPRINT
Volume 84, Issue 2, Pages (August 2013)
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole
Viper venom for diabetic nephropathy
Thinking Beyond New Clinical Guidelines: Update in Hypertension
Step Care Therapy for Hypertension in Diabetic Patients
Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani 
Viper venom for diabetic nephropathy
Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil  Q. Sun, Z-H. Liu, Z. Cheng, J. Chen,
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Volume 63, Issue 3, Pages (March 2003)
Volume 80, Issue 9, Pages (November 2011)
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,
V.M. Campese, N. Mitra, D. Sandee  Kidney International 
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Volume 81, Issue 3, Pages (February 2012)
Volume 70, Issue 11, Pages (December 2006)
Volume 72, Issue 12, Pages (December 2007)
Volume 71, Issue 11, Pages (June 2007)
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension  A. Davenport, C. Cox, R. Thuraisingham  Kidney.
Volume 71, Issue 11, Pages (June 2007)
Treatment of hepatitis B in patients with chronic kidney disease
Volume 71, Issue 6, Pages (March 2007)
Volume 70, Issue 12, Pages (December 2006)
Blood pressure targets in hemodialysis patients
Volume 70, Issue 7, Pages (October 2006)
Fructose intake as a risk factor for kidney stone disease
Volume 72, Issue 12, Pages (December 2007)
Volume 69, Issue 12, Pages (June 2006)
Volume 361, Issue 9352, Pages (January 2003)
Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?  Areef Ishani, Charles A. Herzog,
Arterial function after successful renal transplantation
David M. Charytan, John P. Forman  Kidney International 
Volume 68, Issue 2, Pages (August 2005)
The third World Kidney Day: Looking back and thinking forward
Volume 72, Issue 12, Pages (December 2007)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
The future of renoprotection: Frustration and promises
Isolated Systolic Hypertension: An Update After SPRINT
Volume 69, Issue 8, Pages (April 2006)
Volume 71, Issue 4, Pages (February 2007)
Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter?  Dimitris Mavridis, PhD  American Journal.
Volume 73, Issue 9, Pages (May 2008)
Carmine Zoccali, Francesca Mallamaci  Kidney International 
The course of the remnant kidney model in mice
Volume 73, Issue 5, Pages (March 2008)
Organ transplantation goes to the movies
Volume 72, Issue 3, Pages (August 2007)
Volume 68, Issue 5, Pages (November 2005)
Volume 80, Issue 10, Pages (November 2011)
Hydronephrosis caused by fecal impaction
Is it the low-protein diet or simply the salt restriction?
Volume 69, Issue 10, Pages (May 2006)
Volume 64, Issue 4, Pages (October 2003)
Volume 70, Issue 3, Pages (August 2006)
Volume 71, Issue 9, Pages (May 2007)
Volume 70, Issue 5, Pages (September 2006)
Membranous nephropathy: recent travels and new roads ahead
T cells and T-cell receptors in acute renal failure
Volume 70, Issue 10, Pages (November 2006)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 57, Issue 2, Pages (October 2000)
Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.
Proteinuria and hypertension with tyrosine kinase inhibitors
Antonio Piccoli, Luana Pillon  Kidney International 
Presentation transcript:

Membranous nephropathy: When and how to treat K.N. Lai  Kidney International  Volume 71, Issue 9, Pages 841-843 (May 2007) DOI: 10.1038/sj.ki.5002201 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Treatment algorithm for idiopathic membranous nephropathy. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CsA, cyclosporine; FK506, tacrolimus; MMF, mycophenolate mofetil; RFT, renal function test; Up, urinary protein. Kidney International 2007 71, 841-843DOI: (10.1038/sj.ki.5002201) Copyright © 2007 International Society of Nephrology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.